Homocisteina Formula

Homocisteina Formula cu: TMG-Trimetilglicina 500 mg, Vitamina B6-50 mg, Vitamina B12 500 mcg, Acid Folic 800 mcg.

Procesul vital de bio metilare a homocisteinei - metabolizarea homocisteinei.

Homocisteina Formula

3. Homocisteina ca factor opstructiv arterial (ateroscleroza) si venos (tromboza)

4. Efectul de terapie cu agenti de chelatizare EDTA - Acid etilendiaminotetraacetic si terapia cu Vitamina B asupra endoteliului cu functie de vasodilatatie (oxidul nitric)

5. Homocisteina ca factor de risc in infarctul miocardic

6. Homocisteina ca factor de risc in accidentul vascular cerebral

7. Homocisteina ca factor de risc in retinopatie diabetica si nefropatie

8. Metabolizarea homocisteinei, riscul bolilor cardiovasculare importanta statusului nutritional de Acid folic, Vitamina B6, Vitamina B12

9. Metabolizarea homocisteinei se desfasoara pe doua cai: metilare si transulfuratie a homocisteinei

- Procesul vital de bio metilare a homocisteinei pentru regenerarea de L-Metionina

- Procesul de transulfuratie a homocisteinei, care este catalizat de enzima cistationin beta sintaza dependent de coenzima piridoxal-fosfat pentru formarea de cistationina, apoi cistationina este convertita in L-Cisteina prin enzima cistationin g-liaza deasemenea dependent de coenzima piridoxal-fosfat.

Radicalul CH3 = se numeste grupa metil

TMG-Trimetilglicina este un metabolit al colinei

- TMG-Trimetilglicina este solubila in apa si la gust dulce
- TMG-Trimetilglicina se mai numeste: N,N,N-Trimetilglicina, betaina anhidru, betaina glicina , betaina glicocol, oxineurina si licina.

10. TMG-Trimetilglicina participa ca donator (transfer) de grupa de metil in procesul de metilare a homocisteinei folosind catalizatori Vitamina B6, Vitamina B12 (forma metil cobalamina) si Acid folic (tetrahidrofolat)

Ciclul de metilare a homocisteinei

- TMG-Trimetilglicina participa ca donator (transfer) de grupa metil homocisteinei devenind DMG: N,N,Dimetilglicina (Dimetilglicocol) prin enzima betaina-homocinstein metiltransferaza (BHMT).

Vitamina B6 (Piridoxina HCl)

11. Vitamina B6 indicat in tratamentul de carpal tunel sindrom (Carpal tunnel syndrome) dublu studiu orb randomizat

12. Vitamina B6 indicat in tratamentul sindromului premenstrual (PMS)

13. Vitamina B6 previne infarctul miocardic

Vitamin B12 (Cobalamina)

Vitamina B12 forma de coenzima: Metil cobalamina, este catalizator pentru enzima sintezei de L-Metionina,
Vitamina B12 forma de coenzima: Adenozil cobalamina (5-deoxiadenosilcobalamina) este cofactor enzimei L-metilmalonil coenzyme A (metilmalonil-CoA) mutaza care catalizeaza conversia homocisteinei in L-Metionina

14. Vitamina B12 (forma metil cobalamina) participa ca donator de o grupa de metil in procesul de metilare a homocisteinei pentru sinteza de L-Metionina, iar 5-metiltetrahidrate participa ca donator de o grupa metil pentru regenerarea de Vitamina B12 (forma metil cobalamina)

Acid folic

- Acid folic- Acid tetrahidrofolic numit si (6S)-H4folat sau (6S)-5,6,7,8-tetrahidrofolat sau [(6S)-5,6,7,8-tetrahidropteroilglutamate]

Acidul tetrahidrofolic este catalizat in 5,10-Metilen tetrahidrofolat prin enzima serina hidroxi metiltransferaza.

Radicalul CH2 = se numeste grupa metilen

15. Acidul folic scade hiperhomocisteinemia datorita enzimei 5,10-metilen tetrahidrofolat reductaza (MTHFR) care catalizeaza conversia 5,10-metilen tetrahidrofolat in 5-Metiltetrahidrofolat

- 5,10-Metilen tetrahidrofolat poate transfera un carbon rezidu la deoxiuridilic acid formind timidilic acid,
- 5,10-Metilen tetrahydrofolat se poate transforma in formiltetrahidrofolat care poate dona un carbon in noua sinteza de purin nucleotid.

Sinteza Metionina - Ciclul Acidului folic

- Homocisteina mai poate fi metabolizata in L-Cisteina, catalizator fiind Vitamina B6 (piridoxina).

- Homocistinuria are predispozitie genetica si apare in una din aceste trei forme

16. Vitamina B6 indicat in tratamentul de homocistinurie datorita enzimei cistationin beta-sintaza, enzima (dependenta de Vitamina B6) care produce conversia homocisteinei in cistationina si este un precursor al aminoacidului L-Cisteina

17. Acid folic indicat in anemiile megaloblastice datorita deficientei de acid folic care este cofactor in reactia de L-Metionin sinteza

18. TMG-Trimetilglicina indicat in anemia pernicioasa (dependenta deVitamina B12) datorita unui defect in sinteza metil cobalamina cofactor si catalizator pentru enzima sintezei de L-Metionina

19. Spirulina cu continutul de Vitamina B12 un predominant cobamid (Aqua cobalamin), un aliment care mentine sanatatea

20. Trimetilglicina-TMG indicat la homocistinuria care are cauza genetica si enzimatica

21. Acid folic reduce numarul de cazuri de spina bifida si defect de tub neural

Cursa de metilare (methyl trap hypothesis).

In absenta de Vitamina B12 (forma metilcobalamina) nu se poate forma conversia 5,10-metilen tetrahidrofolat in 5-Metiltetrahidrofolat prin enzima 5,10-metilen tetrahidrofolat reductaza (MTHFR), nu poate fi reconvertit in acid tetrahidrofolic (Acid folic) - Ciclul Acidului folic.

Absenta de Vitamina B12 formeaza cursa de metilare (methyl trap), cauzeaza reducerea sintezei tetrahidrofolat cu consecinta reducerii sintezei de L-Metionina si implicit reducerea conversiei in SAMe-Sulf adenozil metionina.

Sumar: Reducerea de Vitamina B12 rezulta reducerea de biosinteza nucleotidelor purinice precursor sintezei ADN (acid timidilic si purinelor), rezulta inhibarea sintezei ADN si replicarea celulara si in final se ajunge la anemiile megaloblastice

Anemiile megaloblastice induse de Vitamina B12 este cauzata de deficienta functionala celulara a Acidului folic cea ce poate fi corectat prin administrare de suplimente nutritive cu Acid folic.

22. Rolul si functia de Vitamina B12 si Acid folic in sistemul nervos central la oamenii in virsta

23. Deficienta de Vitamina B12 cauzeaza reducerea sintezei tetrahidrofolat si astfel a reducerii sintezei de L-Metionina, implicit reducerea conversiei in S-adenozil-metionina (indicat la depresie)

Reducerea de SAMe-Sulf adenozil metioninaare ca rezultat reducerea de transmetilare la care participa acizi nucleici, fosfolipide si proteine pentru producerea de epinefrina, creatina, melatonina hormon (Anti Aging)

24. Vitamina B12 si Acid folic previne boala Alzheimer

25. Acid folic, Vitamina B12, Vitamina B6 previne bolile neuropsihiatrice

26. Vitamina B12 forma de coenzima: Adenozil cobalamina (5-deoxiadenozilcobalamina) este cofactor enzimei L-metilmalonil-CoA

Incluzind BCAA (branched-chain amino acids), aminoacizii L-Isoleucina, L-Leucina, L-Valina, ca si L-Metionina, L-Treonina, L-Tirozina, sint metabolizati de metilmalonil semi aldehida sau propionil-CoA in metilmalonil-CoA.

Enzima L-metilmalonil CoA mutaza catalizeaza metilmalonil-CoA in succinil-CoA in mitocondrie.

Succinil-CoA poate fi metabolizat in acidul tricarboxilic care produce energie si este involvat in sinteza acizilor grasi.

27. Homocisteina este un factor de risc pentru arteroscleroza, peste un nivel de 12.0 micromol/litru creste riscul bolilor coronariene

Homocisteina este un factor de risc pentru arteroscleroza, peste un nivel de 12.0 micromol/litru creste riscul bolilor coronariene

Reducerea homocisteinei prin adaugarea de suplimente nutritive de TMG-Trimetilglicina, Acid folic, Vitamina B6 si Vitamina B12 previne riscul bolilor coronariene.

- Sinteza SAMe-Sulf adenozil metionina

28. Trimetilglicina-TMG este precursorul la L-Metionina iar L-Metionina este precursorul de SAMe-Sulf adenozil metionina

SAMe-Sulf adenozil metionina este un agent principal de transmetilare la care participa acizi nucleici, fosfolipide si proteine pentru producerea de epinefrina, creatina, melatonina hormon (Anti Aging).

Bibliografie-Referinte:

Informatii din bibliografia electronica la tema: Nutritie si sanatate

1. Barak AJ, Tuma DJ. Betaine, metabolic by-product or vital methylating agent Life Sci. 1983; 32:771-774.
2. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol. 1969 Jul;56(1):111-28.
- McCully KS. Homocystinuria, arteriosclerosis, methylmalonic aciduria, and methyltransferase deficiency: a key case revisited. Nutr Rev. 1992 Jan;50(1):7-12.
- Mudd SH, Edwards WA, Loeb PM, Brown MS, Laster L. Homocysteinuria due to cystatione synthase deficiency; The effect of Pyridoxine. J Clin Invest 1970; 49: 1762–73.
- Skovby F. Homocystinuria. Clinical, biochemical and genetic aspects of cystathionine beta-synthase and its deficiency in man. Acta Paediatr Scand 1985; 321:1–21.
3. Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost. 1999 Feb;81(2):165-76.
- Cattaneo M. Hyperhomocysteinemia: a risk factor for arterial and venous thrombotic disease. Int J Clin Lab Res. 1997;27(3):139-44.
- Kang SS, Wong PW, Malinow MR. Hyperhomocysteinemia as risk factor for occlusive vascular disease. Annu Rev Nutr 1992; 43: 1279 –98.
- Jacobsen DW, Gatautis VJ, Green R, Robinson K, Savon SR, Secic M. Sylvia de Jong. Hyperhomocysteinemia in Patients with Peripheral Arterial Occlusive Disease. Clin Che Lab Med 2001; 39: 714 –6.
4. Green DJ, O'Driscoll JG, Maiorana A, Scrimgeour NB, Weerasooriya R, Taylor RR. Effects of chelation with EDTA and vitamin B therapy on nitric oxide-related endothelial vasodilator function. Clin Exp Pharmacol Physiol. 1999 Nov;26(11):853-6.
5. Israelsson B, Brattstrom LE, Hultberg BL.Homocysteine and myocardial infarction.Atherosclerosis. 1988 Jun;71(2-3):227-33.
6. Perry IJ. Serum total homocysteine concentration and risk of stroke. Lancet. 1996 Nov 30;348(9040):1526.
- Perry IJ. Homocysteine and risk of stroke. J Cardiovasc Risk. 1999 Aug;6(4):235-40. Review.
- Sachdev PS, Valenzuela MJ, Brodaty H, et al. Homocysteine as a risk factor for cognitive impairment in stroke patients. Dement Geriatr Cogn Disord. 2003;15(3):155-62.
7. Hulberg B, Agardh E, Andersson A. Increased levels of plasma homocysteine are associated with nephropathy but not severe retinopapathy in type 1 diabetes mellitus. Scand J Clin Lab Invest 1991; 51: 277–82.
8. Aleman G, Tovar AR, Torres N. Homocysteine metabolism and risk of cardiovascular diseases: importance of the nutritional status on folic acid, vitamins B6 and B12. Depto. Fisiologia de la Nutricion, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, D.F. Rev Invest Clin. 2001 Mar-Apr;53(2):141-51.
- Lobo A, Naso A, Arheart K, Kruger WD, Abou-Ghazala T, Alsous F, Nahlawi M, Gupta A, Moustapha A, van Lente F, Jacobsen DW, Robinson K. Reduction of homocysteine levels in coronary artery disease by low-dose folic acid combined with vitamins B6 and B12. Department of Cardiology, The Cleveland Clinic Foundation, Ohio 44195, USA. Am J Cardiol. 1999 Mar 15;83(6):821-5.
- Aronow WS, Ahn C. Association between plasma homocysteine and coronary artery disease in older persons. Hebrew Hospital Home, Bronx, New York 10475, USA. Am J Cardiol. 1997 Nov 1;80(9):1216-8.
- Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med 1998; 49: 31–62.
- Graeme J Hankey, John W Eikelboom. Homocysteine and vascular disease. The Lancet 1999; 354: 407–13.
- Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet 1999; 354: 407–13.
9. Selhub J, Miller JW: The pathogenesis of homocystenemia: interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine. Am J Clin Nutr 1992; 55: 131-138
10. Jacob RA. Folate, DNA methylation, and gene expression: factors of nature and nurture. Am J Clin Nutr. 2000; 72:903-904.
11. Ellis J, Folkers K, Watanabe T, et al. Clinical results of a cross-over treatment with pyridoxine and placebo of the carpal tunnel syndrome. Am J Clin Nutr. 1979; 32:2040-2046.
- Spooner GR, Desai HB, Angel JF, et al. Using pyridoxine to treat carpal tunnel syndrome. Randomized control trial. Can Fam Physician. 1993; 39:2122-2127.
- Stransky M, Rubin A, Lava NS, Lazaro RP. Treatment of carpal tunnel syndrome with vitamin B6: a double-blind study. South Med J. 1989; 82:841-842.
- Bernstein AL, Dinesen JS. Brief communication: effect of pharmacologic doses of vitamin B6 on carpal tunnel syndrome, electroencephalographic results, and pain. J Am Coll Nutr. 1993; 12:73-76.
- Franzblau A, Rock CL, Werner RA, et al. The relationship of vitamin B6 status to median nerve function and carpal tunnel syndrome among active industrial workers. J Occup Environ Med. 1996; 38:485-491.
- Laso Guzman FJ, Gonzalez-Buitrago JM, de Arriba F, et al. Carpal tunnel syndrome and vitamin B6. Klin Wochenschr. 1989; 67:38-41.
12. Wyatt KM, Dimmock PW, Jones PW, Shaughn O'Brien PM. Efficacy of vitamin B6 in the treatment of premenstrual syndrome: systemic review. Br Med J. 1999; 318:1375-1381.
13. Ellis JM, McCully KS. Prevention of myocardial infarction by vitamin B6. Res Commun Mol Pathol Pharmacol. 1995 Aug;89(2):208-20.
14. Drennan CL, Huang S, Drummond JT, et al. How a protein binds B12: A 3.0 A X-ray structure of B12-binding domains of methionine synthase. Science. 1994; 266:1669-1674.
15. Guenther BD, Sheppard CA, Tran P, et al. The structure and properties of methylenetetrahydrofolate reductase from Escherichia coli suggest how folate ameliorates human hyperhomocysteinemia. Nature Struct Biol. 1999; 6:359-365.
16. Wilcken DE, Dudman NP, Tyrrell PA. Homocystinuria due to cystathionine beta-synthase deficiency - the effects of betaine treatment in pyridoxine-responsive patients. Metabolism. 1985; 34:1115-1121.
- Wilcken DE, Wilcken B, Dudman NP, Tyrrell PA. Homocystinuria - the effects of betaine in the treatment of patients not responsive to pyridoxine. N Engl J Med. 1983; 309:448-453
- Mudd SH, Skovby F, Levy HL et al. The natural history of homocysteinuria due to b-synthase deficiency. Am J Hum Genet 1985; 37: 26 –31.24: 721–35.
17. Wendel U, Bremer HJ. Betaine in the treatment of homocystinuria due to 5,10-methylenetetrahydrofolate reductase deficiency. Eur J Pediatr. 1984; 142:147-150.
- Holme E, Kjellman B, Ronge E. Betaine for treatment of homocystinuria caused by methylenetetrahydrofolate reductase deficiency. Arch Dis Childhood. 1989; 64:1064.
18. Carmel R, Melnyk S, James SJ.Cobalamin deficiency with and without neurologic abnormalities: differences in homocysteine and methionine metabolism.Department of Medicine, New York Methodist Hospital, Brooklyn, NY, USA. rac9001@nyp.org Blood. 2003 Apr 15;101(8):3302-8. Epub 2002 Dec 19.
19. Watanabe F, Katsura H, Takenaka S, et al. Pseudovitamin B12 is the predominant cobamide of an algal health food, spirulina tablets. J Agric Food Chem. 1999; 47:4736-4741.
20. Holme E, Kjellman B, Ronge E. Betaine for treatment of homocystinuria caused by methylenetetrahydrofolate reductase deficiency. Arch Dis Childhood. 1989; 64:1064.
- Mudd SH, Finkelstein JD, Irreverre F, Laster L. Homocystinuria: an enzymatic defect. Science 1964; 143: 1443-5.
- Linnebank M, Homberger A, Junker R, Nowak-Goettl U, Harnis E, Koch HG. High prevalence of I278T mutation of the human cystathionine b-synthase detected by a novel screening application. Thromb Haemost 2001; 85(6): 986-8.
- Adams M, Smith PD, Martin D, Thompson JR, Lodwick D, Samani NJ. Genetic analysis of thermolabile methylenetetrahydrofolate reductase as a risk factor for myocardial infarction. QJM. 1996 Jun;89(6):437-44.
- Deloughery TG, Evans A, Sadeghi A, McWilliams J, Henner WD, Taylor LM Jr, Press RD. Common mutation in methylenetetrahydrofolate reductase. Correlation with homocysteine metabolism and late-onset vascular disease. Circulation. 1996 Dec 15;94(12):3074-8.
- Keijzer M.B.A.J., Den Heijer M., Blom H.J. et al. Interaction between hyperhomocysteinemia, mutated methylenetetrahydrofolatereductase (MTHFR) and inherited thrombophilic factors in recurrent venous thrombosis. [M. Den Heijer, De-partment of Endocrinology, University Medical Center Nijmegen, PO Box 9101, 6500 HB Nijmegen, Netherlands] - THROMB. HAE-MOST. 2002 88/5 (723-728)
21. Anon. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR Morb Mortal Wkly Rep. 1992; 42(RR-14):1-7.
- Berry RJ, Li Z, Erickson JD, et al. Prevention of neural-tube defects with folic acid in China. N Eng J Med. 1999; 341:1485-1490.
defect de tub neural
-Czeizel AE, Dudás I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Eng J Med. 1992; 327:1832-1835.
- Kim Y-I. Folate and Cancer Prevention: A new medical application of folate beyond hyperhomocysteinemia and neural tube defects. Nutr Rev. 1999; 57:314-321.
- MRC Vitamin Study Research Group Prevention of neural tube defects: results of the Medical Council Vitamin Study. Lancet. 1991; 388:131-137.
- Rosenquist TH, Ratashak SA, Selhub J. Homocysteine induces congenital defects of the heart and neural tube: Effect of folic acid. Proc Natl Acad Sci USA. 1996; 93:15227-15232.
- Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. Jean Mayer U.S. Department of Agriculture Human Nutrition Research Center on Aging at Tufts University, Boston, MA 02111,
22. Weir DG, Scott JM. Brain function in the elderly: role of vitamin B12 and folate. Br Med Bull. 1999; 55:669-682.
23. Baik HW, Russell RM. Vitamin B12 deficiency in the elderly. Annu Rev Nutr. 1999; 19:357-377.
- van Asselt DZ, Blom HJ, Zuiderent R, et al. Clinical significance of low cobalamin levels in older hospital patients. Neth J Med. 2000; 57:41-49.
- Kuzuminski AM, Del Giacco EJ, Allen RH, Stabler SP, Lindenbaum J. Effective treatment of cobalamin deficiency with oral cobalamin. Blood. 1998; 92:1191-1198.
-A lpert JE, Fava M. Nutrition and depression: the role of folate. Nutr Rev. 1997; 55:145-149.
24. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer's disease. Arch Neurol. 1998; 55:1449-1455.
- McCaddon A, Kelly CL. Familial Alzheimer's disease and vitamin B12 deficiency. Age Ageing. 1994; 23:334-337.
- Snowdon DA, Tully CL, Smith CD, et al. Serum folate and the severity of atrophy of the neocortex in Alzheimer disease: findings from the Nun Study. Am J Clin Nutr. 2000; 71:993-998.
- McIlroy SP, Dynan KB, Lawson JT, Patterson CC, Passmore AP. Moderately elevated plasma homocysteine methylenetetrahydrofolate reductase genotype and risk for stroke , vas cular dementia and Alzheimer’s disease in Northern Ireland. Stroke. 2002 Oct;33(10): 2351-6.
- Kruman II, Kumaravel TS, Lohani A, et al. Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer’s disease. J Neurosci. 2002 Mar 1;22(5):1752-62.
- Leblhuber F, Walli J, Artner-Dworzak E, et al. Homocysteine and B vitamins in dementia. J Neural Transm. 2000;107(12):1469-74.
- Nourhashemi F, Gillette-Guyonnet S, Andrieu S, et al. Alzheimer’s diseases: protective factors. Am J Clin Nutr. 2000 Feb;71(2):643S-649S.
- Morris MS. Homocysteine and Alzheimer’s disease. Lancet Neurol. 2003 Jul;2(7):425-8.
- Sehardi S, Beiser A, Selhub, J et al. Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. N Engl J Med 2002 Feb 14; 346(7): 476-483.
25. Bottiglieri T. Folate, vitamin B12, and neuropsychiatric disorders. Nutr Rev. 1996; 54:382-390.
- Carmel R, Gott PS, Waters CH, et al. The frequency of low cobalamin levels in dementia usually signify treatable metabolic, neurologic and electrophysiologic abnormalities. Eur J Haematol. 1995; 54:245-253.
-Lindenbaum J, Healton EB, Savage DG, et al. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. N Engl J Med. 1988; 318:1720-1728.
- Bernstein AL. Vitamin B6 in clinical neurology. Ann NY Acad Sci. 1990; 585:250-260.
26. Sumner AE, Chin MM, Abrahm JL, et al. Elevated methylmalonic acid and total homocysteine levels show high prevalence of vitamin B12 deficiency after gastric surgery. Ann Int Med. 1996; 124:469-476.
- Higginbottom MC, Sweetman L, Nyhan WL. A syndrome of methylmalonic aciduria, homocystinuria, megaloblastic anemia and neurological abnormalities in a vitamin B12-deficient breast-fed infant of a strict vegetarian. N Eng J Med. 1978; 299:317-323.
- Herrmann W, Schorr H, Obeid R, Geisel J. Vitamin B-12 status, particularly holo transcobalamin II and methylmalonic acid concentrations, and hyperhomocysteinemia in vegetarians. Am J Clin Nutr. 2003 Jul;78(1):131-6.
27. Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE.Serum total homocysteine and coronary heart disease. Institute of Community Medicine, University of Tromso, Norway. Int J Epidemiol. 1995 Aug;24(4):704-9.
- Bostom AG, Silbershatz H, Rosenberg IH, Selhub J, D'Agostino RB, Wolf PA, Jacques PF, Wilson PW. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women.Tufts Jean Mayer USDA Human Nutrition Research Center on Aging, Boston, Mass, USA. abostom@loa.com Arch Intern Med. 1999 May 24;159(10):1077-80.
- Chang S-J. Vitamin B6 protects vascular endothelial injury by activated platelets. Nutr Res. 1999; 19:1613-1624.
- Ellis JM, McCully KS. Prevention of myocardial infarction by vitamin B6. Res Commun Mol Pathol Pharmacol. 1995; 89:208-220.
- Aybak M, Sermet A, Ayylidiz MO, Karakilcik AZ. Effect of oral pyridoxine hydrochloride supplementation on arterial blood pressure in patients with essential hypertension. Arzneimittelforschung. 1995; 45:1271-1273.
- Jacques PF, Selhub J, Bostom AG, et al. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med. 1999; 340:1449-1454.
- Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 1995; 274:1049-1057.
- Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomized trials. Brit Med J. 1998; 316:894-898.
- Malinow MR, Duell PB, Hess DL, Anderson PH, Kruger WD, Phillipson BE, Gluckman RA, Block PC, Upson BM. Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. Division of Pathobiology and Immunology, Oregon Regional Primate Research Center, Beaverton 97006-3448, USA. N Engl J Med. 1998 Apr 9;338(15):1009-15.
- Woo KS, Chook P, Lolin YI, et al. Folic acid improves arterial endothelial function in adults with hyperhomocysteinemia. J Am Coll Cardiol. 1999; 34:2002-2006.
- Rimm EB, Willett WC, Hu FB, et al. Higher intake of folate and vitamin B6 is associated with low rates of coronary artery disease in women. JAMA. 1998; 279:359-364.
- Kozyraki R, Fyfe J, Kristiansen M, et al. The intrinsic factor-vitamin B12 receptor, cabilin, is a high-affinity apolipoprotein A-1 receptor facilitating endocytosis of high-density lipoprotein. Nat Med. 1999; 5:656-661.
-Title LM, Cummings PM, Giddens K, et al. Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease. J Amer Coll Cardiol. 2000; 36:758-765.
- Voutilainen S, Lakka TA, Porkkala-Sarataho E, et al. Low serum folate concentrations are associated with an excess incidence of acute coronary events: the Kuopio Ischaemic Heart Disease Risk Factor Study. Eur J Clin Nutr. 2000; 54:424-428.
28. Smolin LA, Benevenga NJ, Berlow S. The use of betaine for the treatment of homocystinuria. J Pediatr. 1981; 99:467-472.
- Langdon FW. Nervous and mental manifestations of pre-pernicious anemia. JAMA. 1905; 45:1635-1638.
29. Bell, KM, et al, S-Adenosylmethionine blood levels in major depression: changes with drug treatment. Acta Neurol Scand. 154:15-18, 1994.
- S-Adenosyl-L-Methionine for Treatment of Depression, Osteoarthritis, and Liver Disease. Summary, Evidence Report/Technology Assessment: Number 64. AHRQ Publication No. 02-E033, August 2002. Agency for Healthcare Research and Quality, Rockville, MD.
- Bell, K. M., L. Plon, W. E. Bunney, Jr. and S. G. Potkin (1988). "S-adenosylmethionine treatment of depression: a controlled clinical trial." Am J Psychiatry 145(9): 1110-4.
- Mantero, M., P. Pastorino, A. Carolei and A. Agnoli (1975). "[Controlled double-blind study (SAMe-imipramine) in depressive syndromes]." Minerva Med 66(78): 4098-101.
- Kagan, B. L., D. L. Sultzer, N. Rosenlicht and R. H. Gerner (1990). "Oral S-adenosylmethionine in depression: a randomized, double-blind, placebo-controlled trial." Am J Psychiatry 147(5): 591-5.
- Salmaggi, P., G. M. Bressa, G. Nicchia, M. Coniglio, P. La Greca and C. Le Grazie (1993). "Double-blind, placebo-controlled study of S-adenosyl-L-methionine in depressed postmenopausal women." Psychother Psychosom 59(1): 34-40.
- Baldessarini, RJ, Neuropharmacology of S-Adenosyl Methionine. Am J Med. 83:95-103, 1983.
30. di Padova C. S-adenosylmethionine in the treatment of osteoarthritis. Review of the clinical studies. Am J Med. 1987; 83(5A):60-65.
- Barcelo HA, Wiemeyer JC, Sagasta CL, Macias M, Barreira JC. [Experimental osteoarthritis and its course when treated with S-adenosyl-L-methionine]. RevClin Esp 1990 Jun;187(2):74-8.
- Glorioso, S., S. Todesco, A. Mazzi, R. Marcolongo, M. Giordano, B. Colombo, G. Cherie-Ligniere, L. Mattara, G. Leardini, M. Passeri and et al. (1985). "Double-blind multicentre study of the activity of S-adenosylmethionine in hip and knee osteoarthritis." Int J Clin Pharmacol Res 5(1): 39-49.
- Bradley, J. D., D. Flusser, B. P. Katz, H. R. Schumacher, Jr., K. D. Brandt, M. A. Chambers and L. J. Zonay (1994). "A randomized, double blind, placebo controlled trial of intravenous loading with S-adenosylmethionine (SAM) followed by oral SAM therapy in patients with knee osteoarthritis." J Rheumatol 21(5): 905-11.
31. Jacobsen, S., B. Danneskiold-Samsoe and R. B. Andersen (1991). "Oral S-adenosylmethionine in primary fibromyalgia. Double-blind clinical evaluation." Scand J Rheumatol 20(4): 294-302.
- Tavoni, A., C. Vitali, S. Bombardieri and G. Pasero (1987). "Evaluation of S-adenosylmethionine in primary fibromyalgia. A double- blind crossover study." Am J Med 83(5A): 107-10.
- Volkmann, H., J. Norregaard, S. Jacobsen, B. Danneskiold-Samsoe, G. Knoke and D. Nehrdich (1997). "Double-blind, placebo-controlled cross-over study of intravenous S- adenosyl-L-methionine in patients with fibromyalgia." Scand J Rheumatol 26(3): 206-11.
32. Mato, J. M., J. Camara, J. Fernandez de Paz, L. Caballeria, S. Coll, A. Caballero, L. Garcia-Buey, J. Beltran, V. Benita, J. Caballeria, R. Sola, R. Moreno-Otero, F. Barrao, A. Martin-Duce, J. A. Correa, A. Pares, E. Barrao, I. Garcia-Magaz, J. L. Puerta, J. Moreno, G. Boissard, P. Ortiz and J. Rodes (1999). "S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial." J Hepatol 30(6): 1081-9.
- Ideo, G. (1975). "[S-Adenosylmethionine: plasma levels in hepatic cirrhosis and preliminary results of its clinical use in hepatology. Double-blind study]." Minerva Med 66(33): 1571-80.
- Labo, G., F. Miglio, A. D'Ambro, A. Bellobuono, G. Ideo, N. Dioguardi, M. Bernardi, G. R. Corazza, G. Gasbarrini, P. Avogaro and M. Pasquino (1975). "Double-blind polycentric study of the action of S-adenosylmethionine in hepatic cirrhosis." Minerva Med 66(33): 1590-4.
33. A high-dose version of the Methyl Formula causes dramatic increases in SAMe levels (results on a patient with homocystinuria, T. Kishi, et at 1994).
- Brower IA, Verhoef P, Urgert R. Betaine supplementation and plasma homocysteine in healthy volunteers. Arch Inter Med. 2000; 160:2546-2547.
34. Junnila M, Barak AJ, Beckenhauer HC, Rahko T. Betaine reduces hepatic lipidosis induced by carbon tetrachloride in Sprague-Dawley rats. Vet Hum Toxicol. 1998; 40:263-266.
- Wettstein M, Weik C, Holneicher C, Haussinger D. Betaine as an osmolyte in rat liver: metabolism and cell-to-cell interactions. J Hepatol. 1998; 27:787-793.
35. Barak AJ, Beckenhauser HC, Badakhsh S, Tuma DJ. The effect of betaine in reversing alcoholic steatosis. Alcohol Clin Exp Res. 1997; 21:1100-1102.
- Barak AJ, Beckenhauser HC, Tuma DJ. Betaine effects on hepatic methionine metabolism elicited by short-term ethanol feeding. Alcohol. 1996; 13:483-486.
- Barak AJ, Beckenhauser HC, Tuma DJ. Betaine, ethanol and the liver: a review. Alcohol. 1996; 13:395-398.
36. Song SH, Jong HS, Choi HH, Inoue H, Tanabe T, Kim NK, Bang YJ. Transcriptional silencing of Cyclooxygenase-2 by hyper-methylation of the 5' CpG island in human gastric carcinoma cells. Cancer Research Institute, Seoul National University College of Medicine, Seoul 110-799, Korea.Cancer Res 2001 Aug 1;61(15):5956.
- Morgan SL, Baggott JE, Vaughn WH, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med. 1994; 121:833-841.
37. Anon. Betaine for homocystinuria. Med Lett Drugs Ther. 1997 Jan 31;39(993):12.
- Food and Nutrition Board, Institute of Nutrition. Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and choline. A Report of the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and its Panel on Folate, Other B vitamins, and Choline and Subcommittee on Upper Reference Levels of Nutrients. 1998
- Oakley GP Jr. Eat right and take a multivitamin. N Eng J Med. 1998; 338:1060-1061. *rp Rampersaud GC, Kauwell GPA, Hutson AD, Cerda JJ, Bailey LB. Genomic DNA methylation decreases in response to moderate folate depletion in elderly women. Am J Clin Nutr. 2000:72:998-1003
38. Watanabe F, Katsura H, Takenaka S, et al. Pseudovitamin B12 is the predominant cobamide of an algal health food, spirulina tablets. J Agric Food Chem. 1999; 47:4736-4741.

Literatura

The Methylation Miracle: Unleashing Your Body's Natural Source of SAM-e

by Paul Frankel, Nancy Bruning, Paul, Ph.D. Frankel, Craig Cooney

Parerea din pasajele acestui site nu a fost independent cercetate sau confirmate.